Lisata Therapeutics and GATC Advance AI-driven Opioid Use Disorder Therapy with Deepening Collaboration

Lisata Therapeutics and GATC Health are advancing an AI-driven therapy for opioid use disorder through a deepening partnership. Lisata brings clinical and regulatory expertise, while GATC's MAT platform uses AI to predict drug performance and de-risk development. The collaboration aims to address a significant social issue in the US by leveraging a novel set of targets linked to opioid addiction.

Lisata Therapeutics and GATC Health Corp. have deepened their partnership to advance an AI-driven therapy for opioid use disorder (OUD). This collaboration leverages Lisata's clinical and regulatory expertise with GATC's Multiomics Advanced Technology (MAT) platform, which uses AI to predict drug performance and de-risk development. The initiative aims to address the significant social issue of opioid addiction in the United States.

The partnership builds upon an existing collaboration between the two companies, which initially focused on identifying new AI-predicted combination therapies. The expanded partnership now includes plans to advance GATC's AI-discovered therapeutic for OUD into human clinical trials by early 2026 [2]. This initiative marks a significant step towards developing non-opioid therapies to combat the opioid epidemic.

Lisata Therapeutics, a clinical-stage pharmaceutical company, specializes in developing therapies for advanced solid tumors and other serious diseases. GATC Health Corp., an AI-first biotech company, is known for its MAT platform, which integrates AI with multiomics data to predict drug performance and reduce development risks. The combined expertise of these companies is expected to accelerate the discovery and development of innovative treatments for OUD.

The collaboration is part of a broader trend in the biopharmaceutical industry, where companies are increasingly leveraging AI and machine learning to enhance drug discovery and development processes. According to a recent report, biopharma companies such as AstraZeneca, Lisata, and Juvenescence are partnering with or acquiring AI platforms to accelerate drug discovery [3]. This shift towards data-driven R&D is driven by the need to address significant social issues, such as the opioid epidemic, more effectively and efficiently.

The partnership between Lisata Therapeutics and GATC Health Corp. is a testament to the potential of AI in transforming the drug discovery landscape. By combining clinical and regulatory expertise with advanced AI-driven technologies, the two companies aim to develop novel therapies that can significantly improve outcomes for people living with opioid dependence and other addictions.

References:
[1] https://www.fiercebiotech.com/biotech/eolas-regains-opioid-use-disorder-drug-abandoned-astrazeneca
[2] https://www.decibio.com/insights/ai-machine-learning-june-round-up-2025